5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy

摘要: Background/Aims: There is no standard consensus on a strategy in the second-line setting for gemcitabine-refractory advanced pancreatic cancer. This study evaluated activity and tolerability of oxaliplatin, irinotecan, 5-fluorouracil leucovorin (FOLFIRINOX) as therapy adenocarcinoma pretreated with gemcitabine-based regimen. Methods: A retrospective survey was carried out 18 patients cancer who had been chemotherapy were then treated FOLFIRINOX therapy. Results: One patient (5.6%) confirmed complete response, 4 (22.2%) partial responses 5 (27.8%) stable disease, resulting rate disease control 55.6% (95% CI, 33.3-77.8%). The median progression-free survival 2.8 months 8.4 months, respectively. Seven (38.9%) experienced grade 3-4 neutropenia. Grade 3 or nonhematologic adverse events included nausea vomiting (16.7%). Conclusions: These results suggest modest clinical regarding efficacy acceptable toxicity profile regimen treatment.